New Journal of Association for Vascular Access
publication featuring VALGuard offers health care professionals
Continuing Education Credits as it contributes to their
professional development
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV; OTCQX: CVALF), an advanced medical technologies company, today
announced the publication of an article in the Journal of the
Association for Vascular Access (JAVA), titled “Guarding the
Central Venous Access Device: A New Solution for an Old Problem”,
authored by Darcy Doellman, MSN, RN, VA-BC, a leading expert in
pediatric vascular access. Recently retired from the top-ranked US
Children’s Hospital, Darcy has established herself as a thought
leader in the field of pediatric vascular access, authoring
clinical guidelines, facilitating courses on pediatric intravenous
skills and catheter insertions across the US, and regularly
publishing research in prominent peer reviewed journals.
“Innovation is at the heart of better patient care, but the true
power of new technology lies in how effectively we can communicate
and learn about these breakthroughs,” said Ron Hebert, Senior Vice
President, Marketing, Covalon. “At Covalon we’re incredibly
grateful to JAVA and Darcy for bringing greater awareness to how
Covalon’s VALGuard product can protect and empower more patients
receiving vascular access care. We’re on the frontline of change in
infection prevention and we’re committed to pushing forward this
vital conversation.”
The JAVA article, which was selected by the Journal for CE
(continuing education) marking, aims to update health care
professionals on various sources of CVAD (Central Venous Access
Device) contamination as a major contributor to CLABSIs (Central
line-associated blood stream infections), while highlighting
practices and innovations designed to address the issue. The
majority of CLABSIs are preventable, and strengthening infection
protection bundles with improved practices and new technology is a
proven approach.
In the article, Doellman states, “The actions of our peers and
research on causes of CLABSI favor barrier protection where CVADs
are vulnerable to pathogen entry, for which there is now a
dedicated, safe, and cost-effective solution available.”
Article highlights include:
- CLABSIs are a major concern in both the adult and pediatric
patient population.
- Contamination of catheter hubs is a common cause of
CLABSI.
- VALGuard is a novel, transparent line guard that protects CVAD
hubs from gross contamination.
CLABSIs are serious healthcare-acquired infections associated
with prolonged use of central venous access devices. CLABSIs are a
major concern for all patients, particularly neonatal and pediatric
patients, and for health care providers. In recent times, since the
start of the COVID-19 pandemic, CLABSI rates have risen
significantly, with the United States Center for Disease Control
reporting a 65% CLABSI increase in Intensive Care Units in
2020.
Now, more than ever, new solutions are needed to address
climbing CLABSI rates. VALGuard is a novel, transparent line guard
that helps healthcare providers protect CVAD hubs from gross
contamination and strengthen critical infection prevention bundles,
which play an essential role in keeping patients safe. Covalon is
leading the way in compassionate care solutions designed to help
patients and healthcare professionals prevent infections and
improve outcomes.
For healthcare providers who are interested in learning more
about Covalon’s solutions, visit www.covalon.com or follow Covalon
on LinkedIn, Facebook, Instagram or Twitter.
Reference Doellman, D. Guarding the Central venous Access
Device: A New Solution for an Old Problem. Journal of the
Association for Vascular Access. 2023;28(2):14-18.
About Covalon Covalon Technologies Ltd. is a
patient-driven medical device company, built on the relentless
pursuit to help the most vulnerable patients have a better chance
at healing. Through a strong portfolio of patented technologies and
solutions for advanced wound care, infection prevention, and
medical device coatings, we offer innovative, gentler, and more
compassionate options for patients to heal with less infections,
less pain, and better outcomes. Our solutions are designed for
patients and made for care providers. Covalon leverages its
patented medical technology platforms and expertise in two ways:
(i) by developing products that are sold under Covalon’s name; and
(ii) by developing and commercializing medical products for other
medical companies under development and license contracts. The
Company is listed on the TSX Venture Exchange, having the symbol
COV and trades on the OTCQX Market under the symbol CVALF. To learn
more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results “may”,
“could”, “would”, “might”, “will” or “will be taken”, “occur”, or
“be achieved”. In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management’s expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the “Risks
and Uncertainties” section of our management’s discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which is available on the Company’s
profile at www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230718752876/en/
To learn more about Covalon, please contact:
Brian Pedlar, CEO, Covalon Technologies Ltd. Email:
bpedlar@covalon.com Phone: 905.568.8400 x 233 Toll-Free:
1.877.711.6055 Website: https://covalon.com/ Twitter: @covalon
Covalon Technologies (TSXV:COV)
過去 株価チャート
から 12 2024 まで 1 2025
Covalon Technologies (TSXV:COV)
過去 株価チャート
から 1 2024 まで 1 2025
